A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).
Jacek K. Pinski
No relevant relationships to disclose
Andrew V. Schally
Research Funding - Aeterna Zentaris
Denice D Tsao-Wei
No relevant relationships to disclose
Tanya B. Dorff
No relevant relationships to disclose
Susan G. Groshen
No relevant relationships to disclose
Shigang Xiong
No relevant relationships to disclose
David I. Quinn
No relevant relationships to disclose
Yu-Chong Tai
No relevant relationships to disclose
Juergen Engel
Employment or Leadership Position - Aeterna Zentaris
Stock Ownership - Aeterna Zentaris
Stephen V. Liu
No relevant relationships to disclose